

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 March 2025 (13.03.2025)



(10) International Publication Number
WO 2025/054560 A2

(51) International Patent Classification:
C07K 17/00 (2006.01) A61K 47/68 (2017.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2024/045733

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(22) International Filing Date:
06 September 2024 (06.09.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/581,306 08 September 2023 (08.09.2023) US
63/591,078 17 October 2023 (17.10.2023) US
63/550,023 05 February 2024 (05.02.2024) US

(71) Applicant: NEXTPPOINT THERAPEUTICS, INC.
[US/US]; 238 Main Street, 5th Floor, Cambridge, Massachusetts 02142 (US).

(72) Inventors: ETEMAD-GILBERTSON, Bijan; c/o Next-Point Therapeutics, Inc., 238 Main Street, 5th Floor, Cambridge, Massachusetts 02142 (US). CHARI, Ravi; c/o NextPoint Therapeutics, Inc., 238 Main Street, 5th Floor, Cambridge, Massachusetts 02142 (US).

(74) Agent: LI, Xiaodong et al.; CHOATE, HALL & STEWART LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ANTIBODY-DRUG CONJUGATES

(57) Abstract: Among other things, the present disclosure provides conjugates comprising target binding moieties, payload moieties and linkers. In some embodiments, the present disclosure provides pharmaceutical compositions comprising provided conjugates. In some embodiments, the present disclosure provides methods for preventing or treating various conditions, disorders or diseases using provided conjugates and compositions thereof. In some embodiments, the present disclosure provides technologies for manufacturing provided conjugates and compositions thereof.

WO 2025/054560 A2